|
 |
Clicking a link below will scroll the page down to the relevant section
- A Global Assessment of Medical Morbidities and Quality of Life Among Survivors of Hodgkin's Lymphoma
Straus, David, MD
[Protocol 05-041]
- A Phase I Study of Beta-Glucan and Rituximab in Children and Adolescents with Relapsed CD20-Positive Lymphoma or Leukemia or Post-Transplant Lymphoproliferative Disease
Modak, Shakeel, MD
[Protocol 03-095]
- A Phase I Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
Horwitz, Steven, MD
[Protocol 07-146]
- A Phase I Study of the Safety and Pharmacokinetics of the Proteasome Inhibitor PR-171 in Patients with Hematological Cancers
Comenzo, Raymond, MD
[Protocol 05-137]
- A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Gerecitano, John, MD
[Protocol 05-103]
- A Phase I/II Study of Clofarabine in Patients with Relapsed T-cell and NK-Cell Lymphomas
Horwitz, Steven, MD
[Protocol 06-065]
- A Phase I/II Study of SB-743921 in Patients with Non-Hodgkin's Lymphoma
Gerecitano, John, MD
[Protocol 07-083]
- A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
O'Reilly, Richard, MD
[Protocol 95-024]
- A Phase I/II Trial of Vorinostat in Combination with Cyclophosphamide, Etoposide, Prednisone, and Rituximab for Elderly Patients with Relapsed Diffuse Large B-Cell Lymphoma
Straus, David, MD
[Protocol 08-045]
- A Phase I/IIA Study of Pralatrexate and Gemcitabine with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Lymphoma
Horwitz, Steven, MD
[Protocol 07-062]
- A Phase I/IIa Study Evaluating ABT-263 in Patients with Relapsed or Refractory Lymphoid Malignancies
Gerecitano, John, MD
[Protocol 07-048]
- A Phase II Study of Dose-Escalated Rituximab and ICE for Patients with Primary Refractory and Poor-Risk Relapsed Aggressive B-cell Non-Hodgkin's Lymphoma Undergoing Second-Line Therapy Prior to Stem Cell Transplantation
Moskowitz, Craig, MD
[Protocol 03-075]
- A Phase II Study of R-CHOP and 90Y-Ibritumomab Tiuxetan (Zevalin) for Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Hamlin, Paul, MD
[Protocol 02-090]
- A Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants after a Myeloablative Preparative Regimen for Adult Patients with Lymphohematopoietic Disorders
Jakubowski, Ann, MD, PhD
[Protocol 01-070]
- A Phase II Trial of Liposomal Doxorubicin (Doxil®) Followed by Bexarotene (Targretin®) in Advanced Cutaneous T-Cell Lymphoma
Straus, David, MD
[Protocol 05-098]
- Biaxin (Clarithromycin)-Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
Portlock, Carol, MD
[Protocol 07-038]
- Participation in the National Marrow Donor Program Registry
Kernan, Nancy, MD
[Protocol 90-091]
|
|
|
|